Reporting from: ECCO-13 The European Cancer Conference, Paris, October 30–November 3, 2005 In this edition: Martine Piccart gave the Paris ECCO conference her group’s latest data from the
Reporting from:
ECCO-13 The European Cancer Conference, Paris, October 30–November 3, 2005
In this edition:
Martine Piccart gave the Paris ECCO conference her group’s latest data from the HERA study of breast cancer, recently published in the New England Journal of Medicine. They confirmed that trastuzumab after standard adjuvant therapy extends life for patients with HER2-positive disease.
Edward Romond gave the conference more findings about breast cancer treatment from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding trastuzumab to doxorubicin and cyclophosphamide followed by paclitaxel, and the results confirm te benefit of this targeted agent.
Celestia Higano, presented results from a new study of immunotherapy in hormone refractory prostate cancer. As with earlier trials of chemotherapy, this has now achieved significant improvements in survival.
In cervical cancer, early trial results in over 20,000 women of a vaccine for human papiloma virus suggest that it could go some way toward preventing cervical cancer, according to Jorma Paavonen. In Paris he talked about his group’s work on a vaccine that prioritizes oncogenic subtypes of the virus. Gordon McVie commented on the potential this has worldwide for cervical cancer prevention.
…